D W Visscher
Overview
Explore the profile of D W Visscher including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
72
Citations
524
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Yoon H, Foster N, Meyers J, Steen P, Visscher D, Pillai R, et al.
Ann Oncol
. 2015 Nov;
27(2):339-44.
PMID: 26578722
Background: Carboplatin (C) and paclitaxel (P) are standard treatments for carcinoma of unknown primary (CUP). Everolimus, an mTOR inhibitor, exhibits activity in diverse cancer types. We did a phase II...
2.
Visscher D, Heppner G, Shekhar P
Breast Cancer Res Treat
. 2001 Mar;
65(1):41-7.
PMID: 11245338
We evaluated the effects of tamoxifen on the growth and progression of MCFIOAT xenografts, an estrogen responsive model of human breast tumor progression, in which cells are injected orthotopically into...
3.
Jimenez R, Wallis T, Visscher D
Am J Surg Pathol
. 2001 Feb;
25(3):331-7.
PMID: 11224603
Most breast carcinomas exhibit ductal differentiation. However, recognition of less common histologic patterns provides clinically useful data. This report describes a distinctive subtype of breast carcinoma that we have termed...
4.
Jimenez R, Wallis T, Tabasczka P, Visscher D
Mod Pathol
. 2000 Feb;
13(1):37-45.
PMID: 10658908
Her-2/neu (H2N) status in breast carcinoma has been considered a prognostic factor that may have therapeutic implications; however, the correlation between H2N overexpression and gene amplification has not been completely...
5.
Jimenez R, Bongers S, Bouwman D, Segel M, Visscher D
Am J Surg Pathol
. 2000 Jan;
24(1):123-8.
PMID: 10632496
To assess whether the presence and amount of intraductal component (IC) in diagnostic needle core biopsies (NCB) is predictive of an extensive IC (EIC), the authors evaluated 50 invasive ductal...
6.
Visscher D, Gingrich D, Tabaczka P, Crissman J
Anal Cell Pathol
. 1999 Apr;
17(3):167-75.
PMID: 10221331
Two-color, multiparametric synthesis phase fraction (SPF) analysis of cytokeratin-labeled epithelial cells was flow cytometrically performed on both benign (SPFb) and malignant tissue samples (if available, SPFt) from 132 mastectomy/lumpectomy specimens....
7.
Mendelin J, Grayson M, Wallis T, Visscher D
Lab Invest
. 1999 Apr;
79(4):387-93.
PMID: 10211991
Nonisotopic fluorescence in situ hybridization by using alpha satellite centromeric probes was performed on intact tissue sections of 12 breast carcinomas to compare the pattern of aneuploidy for chromosomes 7,...
8.
Jimenez R, Visscher D
Hum Pathol
. 1998 Dec;
29(12):1412-9.
PMID: 9865826
Breast biopsy or mastectomy cases having diagnoses of carcinoma in situ with "microinvasion," "minimal invasion," "focal invasion," or "suggestive of invasion" were reviewed and all histologically identified foci of invasive...
9.
Nangia-Makker P, Sarvis R, Visscher D, Raz A, Sarkar F
Breast Cancer Res Treat
. 1998 Aug;
49(2):171-83.
PMID: 9696400
Galectin-3 is a galactoside binding protein found at elevated levels in a wide variety of neoplastic cells and thought to be involved in cognitive cellular interactions during transformation and metastasis....
10.
Shekhar M, Nangia-Makker P, WOLMAN S, Tait L, Heppner G, Visscher D
Am J Pathol
. 1998 May;
152(5):1129-32.
PMID: 9588879
We have used the MCF10AT xenograft model of human proliferative breast disease to examine the early effects of estradiol exposure on morphological progression of preneoplastic lesions and to define the...